-+ 0.00%
-+ 0.00%
-+ 0.00%

Prelude Therapeutics names Charles Morris chief medical officer

PUBT·04/15/2026 11:30:57
Listen to the news
Prelude Therapeutics names Charles Morris chief medical officer
  • Prelude Therapeutics named Charles Morris as executive vice president, chief medical officer effective April 20, 2026.
  • Morris most recently served as chief medical officer at Lava Therapeutics.
  • His prior roles include chief medical officer positions at Celyad Oncology, Radius Health, ImmunoGen, and Allos Therapeutics.
  • Prelude cited planned 2026 clinical development starts for lead programs in myeloproliferative neoplasms and ER+ breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150730PRIMZONEFULLFEED9690064) on April 15, 2026, and is solely responsible for the information contained therein.